Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease
This study is testing a new gene therapy called rAAV-Olig001-ASPA for children with Canavan disease. Canavan disease is a serious condition that affects the brain as children grow. The aim of this study is to see how safe the treatment is and if it can help reduce a chemical called NAA, which builds up in the brains of children with Canavan disease. High NAA levels are thought to cause many of the problems seen in the condition. Researchers will also be looking at whether the gene therapy helps children’s movement, language, and other developmental skills over time. This is an early study, meaning it's an important first step in understanding if this new treatment could be helpful.
At a glance
What is this study about?
This clinical trial is designed to investigate a new treatment for Canavan disease, a rare and serious genetic condition that affects the brain. In Canavan disease, the body can't properly break down a chemical called N-Acetylaspartate (NAA), leading to its build-up in the brain. This build-up causes damage to the brain's white matter, which is important for communication between different parts of the brain and the rest of the body. Children with Canavan disease often experience problems with movement, speech, and overall development.
The new treatment being tested is a gene therapy called rAAV-Olig001-ASPA. Gene therapy aims to fix the root cause of certain diseases by delivering healthy copies of genes into the body. In this case, the therapy is given directly into the brain. The hope is that this treatment will help the brain produce the missing enzyme needed to break down NAA, thereby reducing its harmful levels.
This study is in its early stages (Phase 1/2), which means it's an important step where researchers carefully assess the safety of the treatment and start to look for early signs of how well it works. They will be measuring the levels of NAA in the brain and urine, as well as carefully observing children's development, including their movement, language, and thinking skills, to see if the treatment makes a positive difference.
Key takeaways
- This study is testing a new gene therapy for Canavan disease.
- The treatment is given once, directly into the brain.
- Researchers will check if it reduces a harmful chemical (NAA) in the brain.
- They also want to see if it helps with movement and development.
- It's an early-stage study, focused on safety and early signs of how well it works.
Who may be eligible?
This study is looking for children with typical Canavan disease. Both boys and girls can take part, and there are no specific age limits listed in the initial information, meaning children across a range of ages might be considered.
To be eligible, a child would need to have a confirmed diagnosis of Canavan disease. The medical team would conduct a thorough review to make sure the child meets all the necessary health criteria for participating in a gene therapy study.
Because this is a specific treatment for a specific condition, the study will only be suitable for children who have Canavan disease and meet all other health requirements set by the researchers.
Could this study suit you?
Answer these quick questions to see if you may be eligible. This is a guide only — the research team makes the final call.
- Does my child have a confirmed diagnosis of Canavan disease?
- Is my child generally healthy enough to participate in a medical study?
- Am I able to commit to several follow-up visits and assessments?
- Am I comfortable with my child receiving a new type of treatment into their brain?
What does participation involve?
If your child takes part in this study, they would receive a single dose of the gene therapy, which is given into the brain. After the treatment, there would be several follow-up visits over a period of time, at least up to 12 months. These visits are important for the medical team to monitor your child's health and see how the treatment is working.
During these visits, your child would have various assessments. This would include tests to measure chemical levels in their brain fluid (CSF) and urine, and special brain scans called SyMRI to check brain health. They would also have regular checks of their physical development, like movement skills (Gross Motor Function Measure-88), and assessments of their language, thinking, and other developmental abilities (using tests like the MSEL). The total duration of participation and specific schedule of visits would be fully explained by the study team.
Potential risks and benefits
Locations (1)
- —UnverifiedFrance
Common questions
What is gene therapy?
Gene therapy aims to fix diseases by giving the body healthy copies of genes to replace faulty ones. In this study, it's designed to help children with Canavan disease.
What is NAA?
NAA (N-Acetylaspartate) is a chemical that builds up in the brains of children with Canavan disease. High levels of NAA are thought to cause brain damage and developmental problems.
How is the treatment given?
The gene therapy is given as a single dose directly into your child's brain. This helps the treatment get to where it's needed most.
What will researchers be looking for?
Researchers will check if the treatment reduces harmful NAA levels. They'll also monitor your child's movement, language, and overall development to see if improvements occur.
Is this treatment available to everyone?
No, this is a clinical trial, meaning it's still being tested. Only children who meet specific health and diagnostic criteria for Canavan disease can take part.
How to find out more
Always speak to your GP or specialist before deciding to take part in a study.
Discussion
Community discussion
Powered by our forum at community.patient.info. Please be respectful — this is not medical advice.